Abstracts Archive - Page 661 of 2607 - ACR Meeting Abstracts

Abstract Number: 1824 • ACR Convergence 2022
eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy
John Albert¹, Aaron Broadwell², Lissa Padnick-Silver³, Brad Marder⁴ and Brian LaMoreaux³, ¹Rheumatic Disease Center, Glendale, WI, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO
Background/Purpose: Chronic kidney disease (CKD) has been associated with gout1 and CKD worsening has been associated with hyperuricemia.2,3 Pegloticase can lower serum uric acid (sUA)…
Abstract Number: 1823 • ACR Convergence 2022
Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
Tamer A Gheita¹, Ahmed M Elsaman², Aly Bakhiet³, Mohamed Bakrey Mahmoud⁴, Faten Ismail⁵, Hanan El Saadany⁶, Rawhya R ElShereef⁵, Eman F Mohamed⁷, Mervat I Abd Elazeem⁸, Ayman Eid⁸, Fatma Ali⁵, Mona Hamdy⁵, Reem El Mallah⁹, Reem HA Mohammed¹, Samar Tharwat¹⁰, Rania M Gamal¹¹, Samar Fawzy¹, Soha Senara¹², Hanan M Fathi¹², Adham Aboul Fotouh¹³ and Nevin Hammam¹⁴, ¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ⁶Rheumatology Department, Tanta University, Gharbia, Egypt, ⁷Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, ⁸Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ¹⁰Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, ¹³Egyptian School for Musculoskeletal Ultrasonography (EgySMUS); Egyptian Society of Musculoskeletal and Neuromuscular Sonography (ESMNS), Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA
Background/Purpose: Gout comprises a heterogeneous group of disorders characterized by inflammatory arthritis associated with comorbidities leading to impaired quality of life, and an extensive burden…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 1829 • ACR Convergence 2022
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
Lindsay Helget¹, Anne Davis-Karim², James O'Dell¹, Ted Mikuls³, Jeff Newcomb¹, Maria Androsenko⁴, Mary Brophy⁴, Bryant England¹, Ryan Ferguson⁴, Michael Pillinger⁵, Tuhina Neogi⁶, Hongsheng Wu⁴ and Paul Palevsky⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Boston University School of Medicine, Boston, MA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…
Abstract Number: 1828 • ACR Convergence 2022
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
Rachael Flood¹, Colm Kirby¹, yousef Alammari², David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Imam Mohammad Ibn Saud Islamic University, RIYADH, Ar Riyad, Saudi Arabia
Background/Purpose: Emerging evidence that joints of asymptomatic hyperuricaemic individuals contain monosodium urate (MSU) deposits and that alternative presentations of foot pain occur in hyperuricaemia suggests…
Abstract Number: 1827 • ACR Convergence 2022
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
Ernesto Tovar-Sugrañes, Maria-Carmen Lopez-Gonzalez, Cristina Rodriguez-Alvear, Elisabet Perea-Martinez and Mariano Andrès, Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Standard cardiovascular (CV) risk assessment tool (SCORE, Framingham Heart Study) performed inaccurately in patients with gout and carotid atheroma plaques (thus, at high CV…
Abstract Number: 1831 • ACR Convergence 2022
Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)
Judith Boice¹, Travis Helm¹, Maria Bermudez², Mark Corrigan¹ and Bradford Sippy¹, ¹Tremeau Pharmaceuticals, Inc, Concord, MA, ²Clinical Pharmacology of Miami, LLC, Miami, FL
Background/Purpose: TRM-201 (rofecoxib) is a cyclooxygenase-2 (COX-2) selective inhibitor being developed for the treatment of hemophilic arthropathy (HA) and acute migraine. Previously marketed as VIOXX,…
Abstract Number: 1825 • ACR Convergence 2022
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Shay Brikman¹, Amir Bieber² and Reuven Mader¹, ¹Rheumatic Diseases Unit, Emek Medical Center, Afula, Israel, ²Emek Medical Center, Raanana, Israel
Background/Purpose: Prior studies have shown an association between chondrocalcinosis (CC) and vascular calcifications. In this study, we aimed to assess the presence of vascular calcifications…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Aakriti Arora¹, Lakshmi Jayaram², TEFERA ESHETU³ and FLORINA CONSTANTINESCU³, ¹MedStar Washington Hospital Center, Georgetown University, Washington, DC, ²McGaw Medical Center, Northwestern University, Chicago, IL, ³MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…
Abstract Number: 1838 • ACR Convergence 2022
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
Arielle Bensimon¹, Kristina Chen², Ahmed Noman¹, Erica Yim¹, Jason Xenakis³ and Rohit Aggarwal⁴, ¹Analysis Group, Inc., Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Pfizer Inc., New York, NY, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease characterized by muscle weakness, skin rashes, and elevated risk of associated conditions such as interstitial…
Abstract Number: 1837 • ACR Convergence 2022
Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology
Sonia Pastor Navarro¹, Olga Compán Fernández¹, Marta Ibáñez Martínez¹, Belén Miguel Ibáñez¹, Mireia Molina Pérez², Ángel Beltrán Mazo², Olga Martínez González¹, Carlos Montilla Morales¹, Ana Isabel Turrión Nieves¹, Susana Gómez Castro³ and Cristina Hidalgo Calleja¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³Hospital Universitario Salamanca, Salamanca, Spain
Background/Purpose: Ocular inflammatory involvement for being closely related to systemic autoimmune diseases is monitored and treated in our rheumatology visits. The most frequently studied by…
Abstract Number: 1839 • ACR Convergence 2022
Appendicitis Still a Challenge for FMF Patients?
Şura Nur Başpınar¹, Arif Alkan², Mebrure Burcak Yuzbasioglu³, Selcan Yenigun³, Ali Yagiz Ayla⁴, Ibrahim Durucan², Mert Candan², Ali Karabiçek², Çağrı Belli², Tuğba Bayraktar², Helin Idil Besiroglu², Huri Ozdogan⁵ and Serdal Ugurlu⁴, ¹İstanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa Medical Faculty, Istanbul, Turkey, ³Istanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpaşa, Istanbul, Turkey, ⁵Istanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disease that is characterized by recurrent episodes of polyserositis. Episodes typically consist of fever, peritonitis, and…
Abstract Number: 1841 • ACR Convergence 2022
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
María Paula Álvarez Hernández¹, Alfredo Madrid-García², Alejandro Gómez Gómez³, Lara Borrego Sanz⁴, Rosalía Méndez Fernández⁴, Pedro Arriola Villalobos⁴, Esperanza Pato Cour⁵, David Díaz Valle⁴ and Luis Rodriguez-Rodriguez⁵, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, ³Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁵Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…
Abstract Number: 1835 • ACR Convergence 2022
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
Magdalena Harasimowicz¹, Emily GIlbert², Sarah Yi³ and Rochella Ostrowski⁴, ¹Loyola University Medical Center Department of Internal Medicine, Chicago, IL, ²Loyola University Medical Center Division of Pulmonary and Critical Care Medicine, Maywood, IL, ³Loyola University Stritch School of Medicine, Maywood, IL, ⁴Loyola University Medical Center Division of Rheumatology, Maywood, IL
Background/Purpose: Sarcoidosis is a multiorgan granulomatous disease with a prevalence of 60 per 100,000 in the United States.1 Given the low prevalence of both sarcoidosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].